What American Well (AMWL) Said on Its Q3 Earnings Call
Amwell (AMWL) reported Q3 earnings with virtual primary care visits up 41% YoY, but total platform visits down 30.5%. Gross profit was $26M with a 53% margin. Q4 revenue is forecasted at $48M-$50M, with adjusted EBITDA expected to break even or turn positive. The company raised its full-year 2026 outlook, now expecting revenue of $204M-$206M and a reduced adjusted EBITDA loss. Amwell also discussed potential government contracts, including a nonbinding letter of intent from the VA.
How this was made

The 30-second read
Why it matters
The raised guidance and positive outlook could attract short‑term buying, but execution risk around government contracts remains.
Market read
Amwell’s guidance upgrade is the primary market‑moving element; peers may benefit indirectly.
What to watch
Potential delays in the VA agreement and macro‑economic headwinds could temper revenue growth.
Background
Amwell reported Q3 results with modest profit, improved margins, and a cash pile of $181 M, while noting a decline in total platform visits.
Ticker impact
Amwell raised its full‑year 2026 revenue guidance to $204‑$206 M and narrowed its adjusted‑EBITDA loss to $6.9‑$7.9 M, plus gave a Q4 revenue outlook of $48‑$50 M.
likely upward pressure as investors price in higher revenue and tighter loss guidance
The company disclosed materially better guidance than previously expected, a fresh primary fact that can move the stock.
Market effects
Digital‑health peers may see renewed interest as Amwell’s guidance beat expectations.
U.S. telehealth segment could experience modest buying pressure.
Limited; impact confined to U.S. listed telehealth stocks.
Counterpoint
If the VA contract remains non‑binding, the guidance lift may be overstated, risking a pull‑back.
Key entities
- companyAmerican Well (Amwell)
U.S. digital‑health platform provider (NYSE: AMWL).
- governmentDepartment of Veterans Affairs
Potential source of future revenue pending a binding contract.


